Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and capecitabine maintenance in mCRC-NED
NCT05360277Phase 2Recruiting
- Sponsor
- Yanhong Deng
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (metastatic) (mCRC), sponsored by Yanhong Deng. Started Aug 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05360277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360277.